DEEJ(SZ:000423) Sou Hu Cai Jing·2025-10-27 07:13Core Viewpoint - Dong'e Ejiao (SZ000423) reported a revenue increase of 10.10% year-on-year for the first three quarters of 2025, reaching 4.766 billion yuan, and a net profit increase of 10.58%, amounting to 1.274 billion yuan [1] Financial Performance - For the period of July to September 2025, the company achieved a revenue of 1.716 billion yuan, reflecting an 8.50% year-on-year increase, and a net profit of 456 million yuan, which is a 10.29% increase compared to the same period last year [1][2] - After adjustments due to the acquisition of China Resources Pharmaceutical Trading (Hong Kong) Co., Ltd., the revenue growth for the first three quarters of 2025 was revised to 4.41%, and the net profit growth was adjusted to 10.53% [1][2] Acquisition and Strategic Development - In July 2025, the company acquired 100% of China Resources Pharmaceutical Trading (Hong Kong) Co., Ltd. to enhance its overseas business development and promote traditional Chinese medicine culture [1] Key Financial Metrics - Basic earnings per share for the reporting period was 0.7083 yuan, up 10.02% year-on-year [2] - The weighted average return on equity increased to 4.41% from 3.92% year-on-year [2] Leadership Information - Cheng Jie, the chairman of Dong'e Ejiao, has a background in various managerial roles within the pharmaceutical industry and has been with the company in multiple capacities [3][4]